n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Lille, France, Cambridge, Massachusetts, United States, Zurich, Switzerland, January 15, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to the lives of patients with rare and life-saving diseases. diseases. Liver Threatening Disease Company, today announced its provisional monetary schedule for 2024.
2024 Financial Calendar
February 29, 2024
Publication of results and money position as of December 31, 2023
April 4, 2024
Publication of the 2023 Annual Accounts The Universal Registration Document and the 2023 Annual Financial Report (included in the Universal Registration Document), as well as the Annual Report on Form 20-F, will be made public until the end of April 2024.
May 14, 2024
Publication of results and money position as of March 31, 2024
May 22, 2024
Annual Shareholders’ Meeting
September 19, 2024
Publication of the 2024 Half-Year Monetary Statements
November 7, 2024
Publication of results and money position as of September 30, 2024
This schedule is subject to change.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company committed to the lives of patients with rare, life-threatening liver diseases characterized by significant unmet medical needs. GENFIT is a pioneer in liver disease studies and progression, with a rich history and strong clinical legacy spanning more than two decades. Today, GENFIT has a diverse and developing portfolio with systems in other stages of progression. The company’s primary concern is acute and chronic liver failure (ACLF). Its ACLF franchise is made up of five progressive assets: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE. All of these elements are based on differentiated mechanisms of action that exploit complementary pathways. Other assets target other life-threatening disease indications, such as cholangiocarcinoma (CCA) and urea cycle disorders (UCD)/organic acidemias (OA). GENFIT’s ability to bring high-potential early-stage assets to late-stage progression and pre-marketing is highlighted in the successful 52-week Phase 3 ELATIVE® trial comparing elafibranor in PBC. Beyond therapeutics, GENFIT’s portfolio also includes a diagnostic franchise targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), and ammonia. GENFIT is located in Lille and Paris (France), Zuwealthy (Switzerland) and Cambridge, MA (USA). GENFIT is a company indexed on the Nasdaq Global Select Market and in compartment B of the regulated market Euronext in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN becomes one of the main shareholders of GENFIT and owns 8% of the company’s capital. For more information, scale at www. genfit. com
FORWARD LOOKING STATEMENTS
This press release includes certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, among others, statements relating to GENFIT’s studies and progression systems and the release expected monetary. data. The use of safe words, adding “believe”, “prospective”, “expect”, “target”, “possibly” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes that its expectations are based on the existing expectations and conservative assumptions of the Company’s management, such forward-looking statements are subject to known and unknown risks and uncertainties, which may also cause actual effects to differ. materially from those expressed, implied or intended by the forward-looking statements. These dangers and uncertainties include, but are not limited to, the uncertainties inherent in the studies and progression, that is, with respect to the protection of drug candidates, the cost, progress and effects of our ongoing and planned clinical trials, review and approvals through regulatory authorities. in the United States, Europe and around the world, of our drug candidates and diagnostics, the future good fortune of elafibranor if approved, fluctuations in exchange rates, our continued ability to raise capital to fund our progression, as well as such as the dangers and insecurities discussed. or known in the public statements of the Company before the AMF, specifically those indexed in Chapter 2 “Main dangers and insecurities” of the Universal Registration Document of the Company 2022 presented to the AMF. AMF on April 18, 2023, available on the Company’s online page (www. genfit. com) and on the AMF’s online page (www. amf-france. org) and in public documents and reports filed with the Securities and Exchange Commission (“SEC”), adding the Company’s 2022 Annual Report on Form 20-F filed with the SEC. on April 18, 2023 and subsequent filings and reports filed with the AMF or the SEC, adding the semiannual activity and monetary report as of June 30, 2023 or otherwise made public, through the Company. Furthermore, even if the effects, performance, monetary condition and liquidity of the Company, as well as the progression of the industry in which it operates, were consistent with such forward-looking statements, the effects or progressions of the periods of long term. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, the Company undertakes no legal responsibility to update or revise any data or forward-looking statements, whether as a result of new data, long-term events or otherwise.
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | [email protected]
GENFIT | Media
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | [email protected]
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | 333 2016 4000 | www. genfit. com
Attached you
GENFIT Announces Its 2024 Monetary Calendar